APOPTOSIS IN BONE-MARROW BIOPSY SAMPLES INVOLVING STROMAL AND HEMATOPOIETIC-CELLS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Citation
A. Raza et al., APOPTOSIS IN BONE-MARROW BIOPSY SAMPLES INVOLVING STROMAL AND HEMATOPOIETIC-CELLS IN 50 PATIENTS WITH MYELODYSPLASTIC SYNDROMES, Blood, 86(1), 1995, pp. 268-276
Citations number
35
Categorie Soggetti
Hematology
Journal title
BloodACNP
ISSN journal
00064971
Volume
86
Issue
1
Year of publication
1995
Pages
268 - 276
Database
ISI
SICI code
0006-4971(1995)86:1<268:AIBBSI>2.0.ZU;2-#
Abstract
Cell-cycle kinetics were measured in situ after infusions of iododeoxy uridine and/or bromodeoxyuridine in 50 patients with myelodysplastic s yndromes (MDS) and the median labeling index in bone marrow (BM) biops y samples was 28.6%. Unfortunately, 26 of 50 patients showed that grea ter than or equal to 75% of hematopoietic cells of all three lineages were undergoing programmed cell death (PCD) in their biopsy samples as shown by the in situ end labeling (ISEL) technique. Ten patients had 1/3 and eight had 2/3 ISEL(+) cells. Stromal cells were frequently ISE L(+) and often S-phase cells were also found to be simultaneously ISEL (+). Nucleosomal DNA fragments as a ladder in agarose gel were present in BM aspirates of four patients who showed high ISEL and were absent in two who had no ISEL staining in biopsy samples, but only when DNA was extracted after a 4-hour in vitro incubation in complete medium. T herefore, laddering data confirmed the ISEL findings that the majority of hematopoietic cells in MDS are in early stages of PCD. We conclude that extensive intramedullary cell death may explain the paradox of p ancytopenia despite hypercellular marrows in MDS patients. Investigati ng approaches that protect against PCD in some MDS subsets would be of interest. (C) 1995 by The American Society of Hematology.